What are the next steps in management for a patient with Gleason 7 (3+4) prostate adenocarcinoma involving 4% of biopsy cores?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Gleason 7 (3+4) Prostate Adenocarcinoma with 4% Core Involvement

For a patient with Gleason 7 (3+4) prostate adenocarcinoma involving only 4% of biopsy cores, active surveillance is a reasonable management option if the patient meets strict selection criteria, though definitive treatment with radical prostatectomy or radiation therapy plus short-term ADT remains the standard approach for intermediate-risk disease.

Risk Stratification and Treatment Framework

This patient has NCCN favorable intermediate-risk disease (Gleason 3+4, assuming PSA ≤10 ng/ml and clinical stage ≤T2a). The 2024 EAU guidelines provide clear management pathways for this scenario 1.

Active Surveillance Eligibility

The guidelines specifically address Gleason 3+4 for active surveillance, stating you should offer AS to selected patients with ISUP grade group 2 disease when they meet ALL of the following criteria 1:

  • <10% Gleason pattern 4 (this patient qualifies with 3+4 pattern)
  • PSA <10 ng/ml
  • Clinical stage ≤cT2a
  • Low disease extent on imaging
  • ≤3 positive cores with Gleason 3+4
  • ≤50% cancer involvement per core

Critical caveat: The patient must be excluded from active surveillance if biopsy shows cribriform or intraductal histology 1. This is a strong recommendation that cannot be overlooked.

Supporting Evidence for Low-Volume Gleason 3+4

Research strongly supports this approach for low-volume disease. A 2018 study demonstrated that Gleason 3+4 tumors with ≤33% positive cores showed no significant difference in biochemical recurrence risk or cancer-specific mortality compared to Gleason 6 tumors at 10 years 2. More specifically, a 2019 study found that patients with <5% Gleason pattern 4 had similar adverse pathology rates and biochemical recurrence to Gleason 6 cases 3.

With only 4% core involvement, this patient falls well within the favorable range identified in multiple studies 2, 3, 4.

Definitive Treatment Options

If the patient does not meet AS criteria or prefers definitive treatment, the 2024 EAU guidelines recommend 1:

Radical Prostatectomy

  • Offer to patients with >10 year life expectancy
  • Can be safely delayed for at least 3 months if needed for decision-making
  • Nerve-sparing surgery appropriate if low risk of extracapsular disease

Radiation Therapy

For favorable intermediate-risk disease, offer:

  • IMRT/VMAT with IGRT: 76-78 Gy conventional fractionation OR moderate hypofractionation (60 Gy/20 fractions over 4 weeks or 70 Gy/28 fractions over 6 weeks)
  • Combined with short-term ADT (4-6 months)
  • LDR brachytherapy is an option for patients with good urinary function

Alternative: Ultrahypofractionated IMRT/IGRT or SBRT using 36.25 Gy in 5 fractions or 42.7 Gy in 7 fractions on alternate days 1.

Required Workup Before Decision

Before finalizing management, ensure:

  1. MRI imaging if not already performed - required to assess disease extent and exclude higher-risk features 1
  2. Verify absence of cribriform/intraductal carcinoma on pathology review
  3. Confirm PSA level and clinical stage
  4. Calculate life expectancy (>10 years needed for active treatment consideration)
  5. Review total number of positive cores and maximum cancer involvement per core

Active Surveillance Protocol (If Selected)

If AS is chosen, the monitoring protocol requires 1:

  • Repeat biopsies at least once every 3 years for 10 years
  • Do not progress to treatment without repeat biopsy if PSA progression, DRE changes, or MRI changes occur
  • Reclassify and exit AS if repeat biopsies show >3 positive cores or >50% cancer involvement per core of ISUP grade group 2

Common Pitfalls to Avoid

  • Do not assume all Gleason 3+4 is suitable for AS - the percentage of pattern 4 and tumor volume matter significantly
  • Do not overlook cribriform or intraductal patterns - these mandate exclusion from AS 1
  • Do not use less stringent selection criteria - studies show that looser protocols (Royal Marsden, Toronto) result in significantly more adverse pathology compared to strict protocols like PRIAS 5
  • Do not forget short-term ADT with radiation - this is part of the standard recommendation for intermediate-risk disease 1

References

Related Questions

If active surveillance is chosen for a patient with Gleason 3+4 low‑volume prostate cancer, what is the likelihood that the same definitive treatment options (radical prostatectomy or definitive radiation therapy) remain appropriate if disease progression is detected?
What is the prognosis for prostatic adenocarcinoma based on clinical stage, Gleason grade, and serum prostate-specific antigen level?
What is the recommended management for a patient with Gleason 3 + 4 (score 7) prostate cancer and a PSA of 4 ng/mL?
Does a patient with prostate cancer and a Gleason score of 3+4=7 and elevated Prostate-Specific Antigen (PSA) require evaluation for metastatic disease?
For a 67-year-old man with bilateral prostate cancer, Gleason 3+4=7 (Grade Group 2), 7–8 of 10 cores positive, up to 29% tumor involvement and 20% pattern 4, what is the recommended definitive treatment?
Can losartan prevent gout or lower serum uric acid?
Do your tremor and voice symptoms improve when you drink alcohol?
What is the appropriate way to taper and discontinue escitalopram (Lexapro) and increase bupropion (Wellbutrin) dosage in a 39‑year‑old female with major depressive disorder and generalized anxiety disorder who is experiencing bruxism from escitalopram?
In a 40-year-old woman with a 4‑day history of left knee pain after a non‑contact soccer injury, who can bear weight with difficulty, has pain worsened when turning in bed, medial femoral‑condyle tenderness, swelling, and pain on extension testing, what is the most appropriate initial step in management?
For a patient with Gleason 7 (3+4) prostate adenocarcinoma involving only 4% of biopsy cores and otherwise favorable intermediate‑risk disease, is a PET‑CT (including PSMA‑PET) indicated for initial staging?
How should buprenorphine be used concurrently with other opioids, including appropriate dosing, titration, and safety considerations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.